NuCana News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.11.20	NuCana to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
13.10.20	NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar (GlobeNewswire)
21.09.20	NuCana Presents Three Posters at the ESMO Virtual Congress 2020 (GlobeNewswire)
21.09.20	NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares (GlobeNewswire)
17.09.20	NuCana Announces Pricing of a Public Offering of American Depositary Shares (GlobeNewswire)
17.09.20	After Market Hours: Herman Miller, Switchback Energy, Steelcase, Moderna Gain; NuCana Slips (RTTNews)
16.09.20	NuCana Announces Proposed Public Offering of American Depositary Shares (GlobeNewswire)
20.08.20	JNJ Acquires MNTA, FDA Strikes Down BMRN's Gene Therapy, BLRX's GENESIS On Track, TPTX On Watch (RTTNews)
19.08.20	NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
27.05.20	NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference (GlobeNewswire)
21.05.20	ATRA Abuzz, ATOS' COVID-19 Med Effective, INO And VXRT On Track (RTTNews)
19.05.20	NuCana Reports First Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
18.05.20	NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic (GlobeNewswire)
15.05.20	NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 (GlobeNewswire)
05.05.20	NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) (GlobeNewswire)
02.04.20	NuCana Provides Update on Impact of COVID-19 on Clinical Studies (GlobeNewswire)
04.03.20	NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer (GlobeNewswire)
03.03.20	RCEL On The Move, FTSV Acquired, NCNA On Watch, FDA Nod For SNY, COVID-19 Update (RTTNews)
25.02.20	NuCana to Present at the Cowen and Company 40th Annual Health Care Conference (GlobeNewswire)
27.01.20	NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer (GlobeNewswire)
26.11.19	NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference (GlobeNewswire)
14.11.19	NuCana to Present at the Jefferies 2019 London Healthcare Conference (GlobeNewswire)
13.11.19	NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update (GlobeNewswire)
29.10.19	NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
25.10.19	NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer (GlobeNewswire)
29.08.19	NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference (GlobeNewswire)
27.08.19	NuCana to Participate in Citi’s 14th Annual Biotech Conference (GlobeNewswire)
21.08.19	NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update (GlobeNewswire)
20.08.19	Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis (GlobeNewswire)
17.07.19	NuCana Announces First Patients Dosed in Phase I Study of NUC-7738 (GlobeNewswire)
13.06.19	NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer (GlobeNewswire)
30.05.19	NuCana to Present at the Jefferies 2019 Healthcare Conference (GlobeNewswire)
14.05.19	NuCana Reports First Quarter 2019 Financial Results and Provides Business Update (GlobeNewswire)
30.04.19	7 Top Gainers In Pharma Sector (ATHE, NSPR, NCNA…) (RTTNews)
02.04.19	NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference (GlobeNewswire)
14.03.19	8 Top Gainers In Healthcare Sector (AKTX, GH, HJLI...) (RTTNews)
07.03.19	NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update (GlobeNewswire)
05.03.19	NuCana to Present at the Cowen and Company 39th Annual Health Care Conference (GlobeNewswire)
27.02.19	NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019 (GlobeNewswire)
25.01.19	NuCana plc Announces Withdrawal of Public Offering of ADSs (GlobeNewswire)
24.01.19	ADXS Cervical Cancer Trial Put On Hold, GIS Recalls Flour, NCNA, URGN Slump (RTTNews)
23.01.19	NuCana plc Announces Proposed Public Offering of ADSs (GlobeNewswire)
28.11.18	NuCana to Participate in Citi's 2018 Global Healthcare Conference (GlobeNewswire)
27.11.18	NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update (GlobeNewswire)
20.11.18	NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference (GlobeNewswire)
07.11.18	NuCana to Participate in the Jefferies 2018 London Healthcare Conference (GlobeNewswire)
01.11.18	NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer (GlobeNewswire)
31.10.18	IRWD On Watch, Eagle Hurt As Study Fails, NCNA Down Over 30% This Month (RTTNews)
22.10.18	NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018 (GlobeNewswire)
22.10.18	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu NuCana PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten